Ovarian cancer staging: Does it require a gynecologic oncologist?

Allan R. Mayer; Setsuko K. Chambers; Ellen Graves; Carole Holm; Paul C. Tseng; Beth E. Nelson; Peter E. Schwartz

doi:10.1016/0090-8258(92)90110-5

Ovarian cancer staging: Does it require a gynecologic oncologist?

Allan R. Mayer, Setsuko K. Chambers, Ellen Graves, Carole Holm, Paul C. Tseng, Beth E. Nelson, Peter E. Schwartz

Research output: Contribution to journal › Article › peer-review

141 Scopus citations

Abstract

Forty-seven patients with presumed Stages I-II invasive ovarian epithelial carcinoma were treated with intravenous 50 mg/m²cis-platinum, for 2-18 cycles (median, 9), 50 mg/m² doxorubicin for 2-14 cycles (median, 9), and/or 600 mg/m² cyclophosphamide for 2-14 cycles (median, 6) after surgical staging by a gynecologic oncologist or a nononcologic surgeon. Mean follow-up is 6.8 years. Cumulative 5-year actuarial survival is 73 ± 6%; 75 ± 12% for Stage I and 71 ± 8% for Stage II disease. When screened for poor prognosticators, only the specialty of the operating surgeon was identified (P < 0.05). Five-year actuarial survival and disease-free survival, respectively, for Stages I-II patients surgically staged by a gynecologic oncologist were 83 ± 7% and 76 ± 8%, compared to 59 ± 11% (P < 0.05) and 39 ± 11% (P < 0.03) for the group operated upon by a nononcologist.

Original language	English (US)
Pages (from-to)	223-227
Number of pages	5
Journal	Gynecologic oncology
Volume	47
Issue number	2
DOIs	https://doi.org/10.1016/0090-8258(92)90110-5
State	Published - Nov 1992
Externally published	Yes

ASJC Scopus subject areas

Oncology
Obstetrics and Gynecology

Access to Document

10.1016/0090-8258(92)90110-5

Cite this

@article{f77a84e382e74ff9a384ca54a398cd6b,

title = "Ovarian cancer staging: Does it require a gynecologic oncologist?",

abstract = "Forty-seven patients with presumed Stages I-II invasive ovarian epithelial carcinoma were treated with intravenous 50 mg/m2cis-platinum, for 2-18 cycles (median, 9), 50 mg/m2 doxorubicin for 2-14 cycles (median, 9), and/or 600 mg/m2 cyclophosphamide for 2-14 cycles (median, 6) after surgical staging by a gynecologic oncologist or a nononcologic surgeon. Mean follow-up is 6.8 years. Cumulative 5-year actuarial survival is 73 ± 6%; 75 ± 12% for Stage I and 71 ± 8% for Stage II disease. When screened for poor prognosticators, only the specialty of the operating surgeon was identified (P < 0.05). Five-year actuarial survival and disease-free survival, respectively, for Stages I-II patients surgically staged by a gynecologic oncologist were 83 ± 7% and 76 ± 8%, compared to 59 ± 11% (P < 0.05) and 39 ± 11% (P < 0.03) for the group operated upon by a nononcologist.",

author = "Mayer, {Allan R.} and Chambers, {Setsuko K.} and Ellen Graves and Carole Holm and Tseng, {Paul C.} and Nelson, {Beth E.} and Schwartz, {Peter E.}",

year = "1992",

month = nov,

doi = "10.1016/0090-8258(92)90110-5",

language = "English (US)",

volume = "47",

pages = "223--227",

journal = "Gynecologic oncology",

issn = "0090-8258",

publisher = "Academic Press Inc.",

number = "2",

}

TY - JOUR

T1 - Ovarian cancer staging

T2 - Does it require a gynecologic oncologist?

AU - Mayer, Allan R.

AU - Chambers, Setsuko K.

AU - Graves, Ellen

AU - Holm, Carole

AU - Tseng, Paul C.

AU - Nelson, Beth E.

AU - Schwartz, Peter E.

PY - 1992/11

Y1 - 1992/11

N2 - Forty-seven patients with presumed Stages I-II invasive ovarian epithelial carcinoma were treated with intravenous 50 mg/m2cis-platinum, for 2-18 cycles (median, 9), 50 mg/m2 doxorubicin for 2-14 cycles (median, 9), and/or 600 mg/m2 cyclophosphamide for 2-14 cycles (median, 6) after surgical staging by a gynecologic oncologist or a nononcologic surgeon. Mean follow-up is 6.8 years. Cumulative 5-year actuarial survival is 73 ± 6%; 75 ± 12% for Stage I and 71 ± 8% for Stage II disease. When screened for poor prognosticators, only the specialty of the operating surgeon was identified (P < 0.05). Five-year actuarial survival and disease-free survival, respectively, for Stages I-II patients surgically staged by a gynecologic oncologist were 83 ± 7% and 76 ± 8%, compared to 59 ± 11% (P < 0.05) and 39 ± 11% (P < 0.03) for the group operated upon by a nononcologist.

AB - Forty-seven patients with presumed Stages I-II invasive ovarian epithelial carcinoma were treated with intravenous 50 mg/m2cis-platinum, for 2-18 cycles (median, 9), 50 mg/m2 doxorubicin for 2-14 cycles (median, 9), and/or 600 mg/m2 cyclophosphamide for 2-14 cycles (median, 6) after surgical staging by a gynecologic oncologist or a nononcologic surgeon. Mean follow-up is 6.8 years. Cumulative 5-year actuarial survival is 73 ± 6%; 75 ± 12% for Stage I and 71 ± 8% for Stage II disease. When screened for poor prognosticators, only the specialty of the operating surgeon was identified (P < 0.05). Five-year actuarial survival and disease-free survival, respectively, for Stages I-II patients surgically staged by a gynecologic oncologist were 83 ± 7% and 76 ± 8%, compared to 59 ± 11% (P < 0.05) and 39 ± 11% (P < 0.03) for the group operated upon by a nononcologist.

UR - http://www.scopus.com/inward/record.url?scp=0026746752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026746752&partnerID=8YFLogxK

U2 - 10.1016/0090-8258(92)90110-5

DO - 10.1016/0090-8258(92)90110-5

M3 - Article

C2 - 1468701

AN - SCOPUS:0026746752

SN - 0090-8258

VL - 47

SP - 223

EP - 227

JO - Gynecologic oncology

JF - Gynecologic oncology

IS - 2

ER -

Ovarian cancer staging: Does it require a gynecologic oncologist?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this